Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo

Deng, Wenting; Yang, Chuanhong; Xiong, Min; Fu, Xiaoyan; Lai, Hong‐Shiee; Huang, Weixin

doi:10.1016/j.amjoto.2014.07.001

Cited by 12 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 These actions can facilitate the recovery ameliorating the quality of life of patients suffering from BPPV. 50 In support of this theory, Guneri and Kustatun (2012) found that 48 mg of Betahistine daily, in addition to Epley maneuver, gave more effective results than Epley maneuver alone or combined with placebo in improving symptoms in 4 different scales of vertigo symptoms evaluation. 51 On the other hand, Acar et al (2015) sustained that betahistine did not produce any alleviation of RD after some days of treatment.…”

Section: Resultsmentioning

confidence: 97%

See 1 more Smart Citation

Residual Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo: A Review

et al. 2017

View full text Add to dashboard Cite

The benign paroxysmal positional vertigo (BPPV) is a vestibular disorder cause of vertigo. The BPPV may be corrected mechanically by repositioning maneuvers but even after successful maneuvers, some patients report residual dizziness for a certain period afterward. Early recognition and treatment might decrease the incidence of residual dizziness in patients with BPPV, especially in those patients with psychiatric comorbidities and in the elderly, lowering the risk of falling. Many pathogenetic hypotheses for residual dizziness are under debate.The purpose of this review was to identify, evaluate and review recent researches about possible causal factors involved in residual dizziness and the implications on clinical practice. A literature search was performed using different databases such as Pubmed and Scopus. The following search terms were used: residual dizziness, otolithic membrane and BPPV. The search found a total of 1192 titles, which were reduced to 963 after a procedure of de-duplication of the found titles. The research was then restricted to an interval of time comprised between 2000 and 2016 for a total of 800 titles. Among these titles, only those including the terms benign paroxysmal positional vertigo were considered eligible for this review. Only publications in English language were taken into consideration and we excluded those with not available abstract. Finally, 90 abstracts were obtained and critically evaluated by two different Authors, and additional studies were identified by hand searching from the references of artiche of interest. Only 53 were included in this work.

show abstract

Section: Resultsmentioning

confidence: 97%

“…On the basis of these evidences, Deng et al using a randomized double-blinded study, demonstrated that in patients with BPPV, the intravenous administration of Danhong (0.33 ml/kg per day for 5 days) enhanced the recovery from RD after successful repositioning treatment (RD assessed with a RD survey and DHI). 50 …”

Section: Resultsmentioning

confidence: 99%

Residual Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo: A Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…35 These actions can facilitate the recovery ameliorating the quality of life of patients suffering from BPPV. 16…”

Section: Discussionmentioning

confidence: 99%

The Impact of Betahistine versus Dimenhydrinate in the Resolution of Residual Dizziness in Patients with Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial

Jalali

Gerami

Saberi

et al. 2019

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objectives: The aim of this study was to compare the effects of betahistine with dimenhydrinate on the resolution of residual dizziness (RD) of patients with benign paroxysmal positional vertigo (BPPV) after successful Epley maneuver. Methods: In this double-blind, randomized clinical trial, patients with posterior semicircular canal type of BPPV were included. After execution of the Epley maneuver, patients were assigned randomly to one group for 1 week: betahistine, dimenhydrinate or placebo. The primary outcomes were scores of the Dizziness Handicap Inventory (DHI) and the modified Berg balance scale (mBBS). All patients were asked to describe the characteristics of their subjective residual symptoms. Binary logistic regression analysis was performed to examine the predictors of improved RD. All analyses were conducted using SPSS 19.0. Results: In total, 117 patients (age range: 20-65 years) participated in this study. After the Epley maneuver, 88 participants had RD. After the intervention, 38 patients exhibited an improved RD. Less than 50% of participants in the three groups showed mild to moderate dizziness handicap. However, there was no significant difference between mBBS scores of groups before or after the intervention. Logistic regression was shown that patients with receiving betahistine were 3.18 times more likely to have no RD than the placebo group. Increasing age was associated with a decreased likelihood of improving RD ( P = .05). Conclusion: The analysis of data showed that the use of betahistine had more effect on improving RD symptoms. We recommended future studies using objective indicators of residual dizziness.

show abstract

“…According to the basic theory of Chinese medicine, Danhong injection can produce a remarkable curative effect by promoting blood circulation and removing blood stasis. Moreover, numerous studies, both in vivo and in vitro , have validated the vascular protective effects of Danhong injection [ 18 – 22 , 31 , 38 ]. Based on the theoretical and clinical evidence mentioned previously, Danhong injection is regarded as a promising therapeutic option for the treatment of chronic stable angina.…”

Section: Discussionmentioning

confidence: 99%

“…Danhong injection, the profile of which has been analyzed using HPLC, is certified as a Chinese medicinal product by the China Food and Drug Administration. A number of previous studies, from the bench to the bedside, have suggested that the pharmacological mechanisms of Danhong injection might involve anti-inflammatory activity, anti-atherosclerotic activity, and the activation of blood circulation [ 18 – 22 ]. Several clinical studies have also demonstrated that Danhong injection might be an effective and safe treatment option for the management of coronary heart disease [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial

Wang

Dong

et al. 2015

Trials

View full text Add to dashboard Cite

BackgroundChronic stable angina is a leading cause of death worldwide. Danhong injection, a complementary alternative medicine for chronic stable angina, has been demonstrated to be effective in numerous studies and is widely prescribed to patients. However, the methodological quality of most prior studies was found to be, in general, low. Therefore, we designed this randomized controlled trial to evaluate the efficacy and safety of using Danhong injection to treat chronic stable angina.Methods/designThis is a randomized multicentre, double-blind, placebo-controlled, adaptive clinical trial. A total of 870 patients meeting the eligibility criteria will be randomly assigned into either the Danhong injection or the placebo group in a 2:1 ratio. Participants will then undergo a 2-week treatment regimen and a 76-day follow-up period. Because this is an adaptive trial, two interim analyses are prospectively planned. These will be performed after one-third and two-thirds of the patients, respectively, have completed the trial. Based on the results of these interim analyses, a data monitoring committee will determine how to modify aspects of the study without undermining the validity and integrity of the trial. The primary outcome measure is the proportion of patients who show a clinically significant change, which is defined as at least a 20-point improvement in angina frequency score on the Seattle Angina Questionnaire, which will be administered on day 30. Other secondary efficacy and safety outcomes will also be assessed.DiscussionThis trial will provide high-quality evidence regarding the use of Danhong injection to treat chronic stable angina.Trial registrationClinicalTrials.gov: NCT01681316.

show abstract

Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo

Cited by 12 publications

References 31 publications

Residual Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo: A Review

Residual Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo: A Review

The Impact of Betahistine versus Dimenhydrinate in the Resolution of Residual Dizziness in Patients with Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial

Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About